The global Veterinary Contract Manufacturing & Research Market is entering a high-growth phase, projected to expand from USD 1.01 billion in 2026 to USD 1.48 billion by 2031, at a CAGR of 7.9%. As animal health companies face increasing pressure to innovate faster while managing costs, outsourcing across discovery, development, and manufacturing is becoming a strategic imperative.
Browse 586 market data Tables and 71 Figures spread through 494 Pages and in-depth TOC on “Veterinary Contract Manufacturing & Research Market”.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=123382191
What is driving this growth, and why is it gaining momentum now?
The market is witnessing robust expansion fueled by a combination of demographic shifts, economic pressures, and rapid technological advancements. Increasing demand for efficient, scalable, and cost-effective drug development solutions is accelerating outsourcing across vaccines, biologics, and small-molecule therapeutics.
Who is leading this transformation? Animal health companies, veterinary biotech firms, research institutions, and diagnostic laboratories are increasingly collaborating with Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs). These partnerships are enabling organizations to enhance R&D productivity, improve study quality, and significantly shorten time-to-market critical factors in today’s competitive landscape.
How is technology reshaping the industry?
The integration of AI-enabled predictive modeling, digital clinical trial management systems, automated bioprocessing, and advanced analytical platforms is redefining operational efficiency. Additionally, the adoption of scalable single-use systems, cloud-based data platforms, and enhanced quality management tools is improving flexibility, regulatory compliance, and decision-making precision across the veterinary outsourcing ecosystem.
From a product perspective, the medicines segment accounted for the largest market share in 2025. Why does this segment dominate? The continued need for innovative therapeutics—including antibiotics, parasiticides, pain management drugs, and treatments for chronic and infectious diseases—drives sustained R&D activity. As regulatory requirements intensify and formulations become more complex, companies are increasingly relying on external partners for formulation development, scale-up, analytical testing, and GMP-compliant manufacturing.
Looking at end users, startups and veterinary biotech firms are expected to register the highest CAGR during the forecast period. What is fueling their rapid growth? These organizations depend heavily on outsourcing to access advanced infrastructure and specialized expertise. Their focus on cutting-edge innovations such as novel biologics, gene-based therapies, and digital health solutions—combined with rising investor interest, is significantly boosting demand for CDMO and CRO services.
Where is the market expanding most significantly?
North America held the largest market share in 2025, supported by a strong ecosystem of leading animal health companies, advanced R&D infrastructure, and substantial investments in veterinary therapeutics and biologics. High pet healthcare spending, strong regulatory frameworks, and widespread adoption of innovative technologies continue to reinforce the region’s leadership position.
Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=123382191
Market Insights:
Key players shaping the competitive landscape include areva (France), Vetio (US), Aenova Group (Germany), TriRx Pharmaceutical Services (US), Argenta Holdco Limited (UK), Labcorp (US), Eurofins Scientific (Luxembourg), Charles River Laboratories (US), knoell Germany GmbH (Germany), and Evotec (Germany), among others. These companies are focusing on strategic collaborations, capacity expansion, and technology integration to strengthen their market position and meet evolving client demands.
Why does this matter for decision-makers? As global animal health needs continue to rise, outsourcing is no longer a tactical option but a strategic lever for innovation, scalability, and regulatory compliance. Organizations that invest in the right partnerships and technologies today will be better positioned to capture long-term growth opportunities in this rapidly evolving market.
